Compare CENN & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENN | NXL |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.6M |
| IPO Year | 2017 | N/A |
| Metric | CENN | NXL |
|---|---|---|
| Price | $4.09 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.9K | ★ 195.5K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,080,161.00 | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $0.33 |
| 52 Week High | $4.57 | $2.00 |
| Indicator | CENN | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 68.55 | 39.12 |
| Support Level | $0.14 | N/A |
| Resistance Level | $4.50 | $0.46 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 33.89 | 2.74 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, Logimax, Avantier, Teemak, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the United States, and also has a presence in Europe, Asia, and other regions.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.